期刊文献+

多西紫杉醇联合希罗达治疗晚期胃癌的临床观察 被引量:1

下载PDF
导出
摘要 目的:观察多西紫杉醇联合希罗达(DX)方案治疗晚期胃癌的临床疗效和毒副作用。方法:多西紫杉醇70 mg/m2静滴,第1天,希罗达1 000 mg/m2,一天两次,连续14天,21天为一周期。至少连续治疗2个周期后进行评价。结果:全组58例患者均可评价,总有效率60.3%,中位疾病进展时间5.7月,中位生存时间9.6月。血液学毒性主要表现为中性粒细胞减少,Ⅲ~Ⅳ度发生率25%。结论:DX方案治疗晚期胃癌有效率较高,用药方便,住院时间短,毒副反应可以耐受,能明显改善患者的生活质量,可以用于晚期胃癌的治疗,值得在临床上推广。
出处 《赣南医学院学报》 2011年第2期254-254,共1页 JOURNAL OF GANNAN MEDICAL UNIVERSITY
  • 相关文献

参考文献7

二级参考文献67

  • 1沈琳,李洁,张晓东,李燕,张小田,金懋林.PELF方案治疗进展期胃癌68例[J].中国肿瘤临床,2005,32(3):162-164. 被引量:19
  • 2[1]Sasaki T,Maeda Y,Kobayashi T,et al.Standard chemotherapy for gastrointestinal malignancies based on evidence.Jap J Cancer Chemother,2000,27 (20):166
  • 3[4]Jin M,Shen L,Hu B,et al.Mature data on capecitabine (X) + fractionated cisplatin (P) as first-line therapy in patients (pts) with advanced gastric carcinoma (AGC).Proc Am Soc Clin Oncol,2006,24:196S
  • 4[5]Kang Y,Kang WK,Shin DB,et al.Randomized phase Ⅲtrial of capecitabine/cisplatin (XP) vs continuous infusion of 5 -FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):Efficacy and safety results.Proc Am Soc Clin Oncol,2006,24:183S
  • 5[6]Shitara K,Sakata Y,Kudou T,et al.Gastric Cancer:S -1 monotherapy and its progress.Jpn J Cancer Chemother,2006,33 (Suppl I):43
  • 6[7]Ajani JA,Fodor MB,Tjulandin SA,et al.Phase Ⅱ multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric or gastroesophageal adenocarcinoma.J Clin Oncol,2005,23 (24):5660
  • 7[9]Cunningham D,Rao S,Starling N,et al.Randomised multicentie phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patientswith advanced oesophagogastric cancer:The REAL 2 trial.Proc Am Soc Clin Oncol,2006,24:182S
  • 8[10]Park Y,Lee J,Ryoo B,et al.Aphase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer.Proc Am Soc Clin Oncol,2006,24:197S
  • 9[11]Pozzo C,Bugat R,Peschel C,et al.Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastrooesophagealjunction adenocarcin oma:Final results of a randomized phase Ⅱ study.Proc Am Soc Clin Oncol,2000,20:531
  • 10[12]Bouche O,Raoul J,Giovanini M,et al.Randomized phase Ⅱ trial of LV5FU2,LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA):Final results of study FFCD9803,Proc Am Soc Clin Oncol,2003,21,1033

共引文献144

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部